INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $6,000 | +20.0% | 7,000 | 0.0% | 0.00% | – |
| Q4 2020 | $5,000 | 0.0% | 7,000 | +16.7% | 0.00% | – |
| Q3 2020 | $5,000 | 0.0% | 6,000 | 0.0% | 0.00% | – |
| Q2 2020 | $5,000 | -99.8% | 6,000 | -99.7% | 0.00% | -100.0% |
| Q4 2018 | $2,044,000 | -66.1% | 2,218,000 | -62.8% | 0.00% | -50.0% |
| Q3 2018 | $6,031,000 | -13.5% | 5,968,000 | -25.1% | 0.00% | -33.3% |
| Q2 2018 | $6,976,000 | +20.4% | 7,968,000 | +10.2% | 0.00% | 0.0% |
| Q1 2018 | $5,792,000 | +219.5% | 7,229,000 | +217.1% | 0.00% | +200.0% |
| Q4 2017 | $1,813,000 | +70.1% | 2,280,000 | +65.2% | 0.00% | – |
| Q3 2017 | $1,066,000 | -78.3% | 1,380,000 | -72.7% | 0.00% | -100.0% |
| Q2 2017 | $4,909,000 | -34.6% | 5,048,000 | -37.3% | 0.00% | -25.0% |
| Q1 2017 | $7,502,000 | -43.0% | 8,050,000 | -45.5% | 0.00% | -42.9% |
| Q4 2016 | $13,153,000 | +37.5% | 14,758,000 | +72.4% | 0.01% | +16.7% |
| Q3 2016 | $9,569,000 | – | 8,558,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|